Therapy Areas-Hansoh Pharmaceutical Group Co., Ltd.

EN 

About Us
About Us
Overview

History

Honor

Leadership

Contact Us
Continuous innovation for better life

Hansoh Pharma, a leading innovation-driven pharmaceutical company in the PRC, is committed to improving human health through unremitting innovation, focusing mainly on such areas as anti-tumor, anti-infectives, CNS diseases, metabolic diseases, autoimmune diseases.
Innovation
Innovation
Achievements

R&D Platforms

R&D Capability

Business Development

Manufacturing

Quality Management
Continuous innovation for better life

Hansoh Pharma, a leading innovation-driven pharmaceutical company in the PRC, is committed to improving human health through unremitting innovation, focusing mainly on such areas as anti-tumor, anti-infectives, CNS diseases, metabolic diseases, autoimmune diseases.
Products
Products
Our Products

Market Coverage
Continuous innovation for better life

After more than 20 years of continuous investment in R&D, Hansoh Pharma has marketed 7 innovative drugs and has over 30 innovative drug programs in different clinical stages with over 50 clinical trials in progress, forming a rich pipeline.
News
News
Press Releases

Media Center
Hansoh Pharma updates

Find the latest and most complete information about Hansoh Pharma!
Investors
Investors
Company Information

Corporate Governance

Financial Information

Announcements and Circulars

Investor Contact
Continuous innovation for better life

Hansoh Pharma, a leading innovation-driven pharmaceutical company in the PRC, is committed to improving human health through unremitting innovation, focusing mainly on such areas as anti-tumor, anti-infectives, CNS diseases, metabolic diseases, autoimmune diseases.
ESG
ESG
ESG Management

ESG Practice and Honor

ESG Reports
Responsibility integrity diligence innovation

Hansoh Pharma has always focused on corporate governance, corporate behavior, product safety and quality, access to healthcare, human resource development, environmental protection and community enhancement as the focus and the basis of ESG management, and has been continually committed to improving the medicine availability and the innovative development in fields with unmet clinical needs.
Careers
Careers
Work with Us

Join Us
Work with us

We welcome talents worldwide to join us with their entrepreneurship and achieve new levels of success in their career!

About Us 
- Back
- Overview
- History
- Honor
- Leadership
- Contact Us
Innovation 
- Back
- Achievements
- R&D Platforms
- R&D Capability
- Business Development
- Manufacturing
- Quality Management
Products 
- Back
- Our Products
- Market Coverage
News 
- Back
- Press Releases
- Media Center
Investors 
ESG 
- Back
- ESG Management
- ESG Practice and Honor
- ESG Reports
Careers 
- Back
- Work with Us
- Join Us



Related Links

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Therapy Areas

Home > Innovation > Therapy Areas

Achievements R&D Platforms R&D Capability Business Development Manufacturing Quality Management

Therapy areas

Our company focuses on the research and development of new drugs in the therapeutic areas of oncology, anti-infectives, CNS diseases, metabolic diseases and autoimmune diseases. It has established a comprehensive innovative R&D platform, and more than 60 clinical trials of innovative drug candidates being investigated, covering 40 innovative drug candidates.

Anti-tumor

We focus on the develoment of new drugs in the field of common and hostile cancers.Our innovative medicine programs in clinical trials include HS-20106 injection, HS-20105 injection, HS-20117 injection, HS-10516 capsules, HS-10382 tablets, HS-10370 tablets, HS-10502 tablets, HS-10365 capsules, HS-20089 injection, HS-20093 injection, HS-20124 injection, HS-10352 tablets, HS-10241 tablets, HS-10504 tablets, etc.Our product portfolio mainly includes the innovative drug Ameile (aumolertinib mesylate tablets), the innovative drug Hansoh Xinfu (flumatinib mesylate tablets), Pulaile (pemetrexed disodium for injection), Xintai (bortezomib for injection) ,Xinwei (imatinib mesylate tablets) and Tanneng (fosaprepitant dimeglumine for injection).
Anti-infectives

We focus on the development of new drugs in the fields of antiviral, anti-complex bacterial infection and anti-fungal infection. Our innovative medicine programs in clinical trials include Citric Acid Erythorbate tablets, etc.Our product portfolio mainly includes the innovative drug Hengmu (tenofovir amibufenamide tablets), the innovative drug Mailingda (morinidazole sodium chloride injection), Zetan (tigecycline for injection) and Hengsen (micafungin sodium for injection).
CNS Diseases

We focus on the development of new drugs in the fields of psychiatric and neurological disorders.Our innovative medicine programs in clinical trials include HS-10380 tablets, HS-10506 tablets, HS-10353 capsules, HS-10509 tablets, etc. Our product portfolio mainly includes the innovative drug Xinyue (inebilizumab injections, anti-CD19 mAb), Oulanning (olanzapine oral dose formulations), Ailanning (paliperidone extended-release tablets) and Ameining (agomelatine tablets).
Metabolic and others

We focus on the development of new drugs in the field of metabolic diseases such as diabetes and obesity. Our innovative medicine programs in clinical trials include HS-20094 injection, HS-10383 tablets, HS-10384 tablets, HS-10518 capsules, HS-10390 tablets, HS-10501 tablets, and HS-10398 capsules, etc.
Autoimmune Diseases

We focus on the development of new drugs in the field of autoimmune diseases. Our innovative medicine programs in clinical trials includeHS-10374 tablets, HS-10501 capsules, etc.